Clinical trials
Colorectal Cancer Screening clinical trials
Below are recruiting colorectal cancer screening clinical trials, each written for real people, not researchers. We’re tracking 370 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07543744RecruitingPhase 1
Comparing RPH-030 to Vectibix for metastatic colorectal cancer
This trial tests whether a new drug called RPH-030 works similarly to an existing drug called Vectibix in treating advanced colorectal cancer that has spread. Both drugs will be given alongside chemotherapy (FOLFIRI) as a first-line treatment.
ArkhangelskAges 18 years+ - NCT07411599RecruitingPhase 1/Phase 2
CAR-NK cell therapy plus cetuximab for belly-spread colorectal cancer
This trial tests a new cell therapy (CAR-NK cells given directly into your belly and a vein) combined with a targeted drug (cetuximab) for colorectal cancer that has spread mainly to the lining of your belly. It aims to see if this treatment can shrink tumors and help people who have run out of standard chemotherapy options.
Houston, TexasAges 18 years+ - NCT05288205RecruitingPhase 1/Phase 2
JAB-21822 plus JAB-3312 for KRAS G12C solid tumors
This Phase 1/2a trial tests two investigational pills (JAB-21822 and JAB-3312) in people with advanced solid cancers that have a KRAS G12C mutation. It’s for cases where standard treatments have failed or aren’t suitable, to see if the drugs can shrink tumors and improve outcomes.
Hefei, AnhuiAges 18 years+ - NCT06662786RecruitingPhase 3
Amivantamab plus chemo vs. standard chemo for left-sided colorectal cancer
This trial compares a new combination (amivantamab plus chemotherapy) with the standard treatment (cetuximab plus chemotherapy) as the first therapy for people with left-sided colorectal cancer that has spread. The goal is to see which approach works better when the tumor has no mutations in the KRAS, NRAS, or BRAF genes.
Gilbert, ArizonaAges 18 years+ - NCT05253651RecruitingPhase 3
Tucatinib plus trastuzumab with chemo for HER2+ metastatic colon cancer
This trial tests whether adding tucatinib and trastuzumab to standard chemotherapy works better than standard treatment alone for people with HER2-positive metastatic colon or rectal cancer. It aims to improve how long people live and how well tumors respond as first treatment for advanced disease.
Glendale, ArizonaAges 18 years+ - NCT06002789RecruitingPhase 2
PD-1 immunotherapy with or without chemo before surgery for colorectal cancer
This trial tests a medicine called PD-1 (a type of immunotherapy that helps your immune system fight cancer), sometimes with chemotherapy, before surgery for a certain type of colorectal cancer. It is for people whose tumors have a specific DNA repair problem (dMMR or MSI-H) and whose cancer has not spread to distant organs.
Guangzhou, GuangdongAges 18–80 - NCT06204484Recruiting
MRD-guided Chemo Timing for Early Colon Cancer
This trial is for people with early-stage colon cancer (stage II high-risk or stage III low-risk) that is not MSI-H. It uses a blood test (MRD) to see if you can safely delay or skip extra chemotherapy after surgery, based on whether the test finds any leftover cancer cells.
Guangzhou, GuangdongAges 18–70 - NCT06621563RecruitingPhase 1
Study of HS-20117 Combination Therapy for Advanced Solid Tumors
This early-phase trial tests a new drug (HS-20117) combined with other drugs for people with advanced solid tumors. It aims to see if the combination is safe and effective, especially for cancers that have not responded to other treatments.
TianjinAges 18–75 - NCT06839105RecruitingPhase 1
Testing AWT020 for advanced cancers
This study tests an experimental drug called AWT020 in people with advanced cancers that have either stopped responding to standard treatments or aren't candidates for them. The goal is to see if AWT020 is safe and tolerable across several cancer types such as lung cancer, melanoma, colorectal cancer, kidney cancer, and others.
Fuzhou, FujianAges 18 years+ - NCT07091032Recruiting
Building connections for better health
This study tests if helping people address obesity, cancer screenings, or mental health struggles can improve their overall health. You may qualify if you have obesity, are behind on colon or cervical cancer screening, or have depression or anxiety.
Boston, MassachusettsAges 18–75 - NCT07257653RecruitingPhase 2
Cetuximab beta plus fruquintinib with or without immunotherapy for first-line advanced colorectal cancer
This trial tests a combination of two targeted drugs (cetuximab beta and fruquintinib) with or without an immunotherapy drug for people with a specific type of advanced colorectal cancer that has not been treated before. It aims to see if this approach is safe and effective for those whose tumors have certain genetic markers (RAS and BRAF wild type).
Hangzhou, ZhejiangAges 10–85 - NCT07348211RecruitingPhase 1
Study of SIM0610 for advanced solid tumors
This trial tests a new drug called SIM0610 for people with advanced solid tumors that have stopped responding to standard treatments. The study aims to see if the drug is safe and effective.
Chongqing, Chongqing MunicipalityAges 18 years+ - NCT07586813RecruitingPhase 2
Romiplostim N01 Plus ATRA for Low Platelets After Gut Cancer
This trial tests a combination of two medicines (Romiplostim N01 and ATRA) to raise dangerously low platelet counts that sometimes persist after chemotherapy for digestive cancers. If your platelets stay low even after previous platelet-raising treatments, this study may help.
BeijingAges 18 years+ - NCT06428409RecruitingPhase 1/Phase 2
A study of MK-2870 for several gastrointestinal cancers
This trial is testing a new drug called MK-2870, alone or with other treatments, for people with advanced colorectal, pancreatic, or bile duct cancer. It aims to see if the drug can help shrink or control the cancer.
Los Angeles, CaliforniaAges 18 years+ - NCT07463599RecruitingPhase 1/Phase 2
Tegavivint for advanced colorectal cancer after other treatments
This early-phase trial tests an experimental drug called tegavivint for people with advanced colorectal cancer who have already tried several standard treatments. It aims to see if the drug can shrink or slow the growth of tumors.
Scottsdale, ArizonaAges 18 years+ - NCT05824975RecruitingPhase 1/Phase 2
Test drug GI-102 alone or with cancer medicines
This Phase 1/2 study tests whether GI-102 is safe and can help shrink advanced solid tumors. It also looks at GI-102 used with standard cancer treatments like pembrolizumab or trastuzumab deruxtecan (T-DXd).
Scottsdale, ArizonaAges 18 years+ - NCT06534762RecruitingPhase 2
Miraberon for advanced solid tumors (first treatment)
This study tests a drug called Miraberon for people with advanced solid tumors that have not yet been treated with chemotherapy or other cancer drugs. The goal is to see if Miraberon can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–65 - NCT07300150RecruitingPhase 1
PT0511 for KRAS-mutated or amplified advanced solid tumors
This trial tests a new drug called PT0511 that targets a specific gene change (KRAS) found in some advanced solid tumors. It's for people whose cancer has not responded well to other treatments and who are looking for a new option.
Boston, MassachusettsAges 18 years+ - NCT06362369RecruitingPhase 1/Phase 2
Oral 7HP349 with immunotherapy for advanced solid tumors
This trial tests an experimental oral drug (7HP349) combined with two immunotherapy drugs (ipilimumab and nivolumab) for people with advanced solid tumors. It aims to see if the combination is safe and effective in shrinking tumors.
Aurora, ColoradoAges 18 years+ - NCT05176483RecruitingPhase 1
New drug combinations for advanced solid tumors
This trial tests a new drug called zanzalintinib, which may slow or shrink various types of advanced cancer. It is given together with other cancer treatments, and the study is looking at many different cancers including kidney, prostate, bladder, lung, liver, and more.
Phoenix, ArizonaAges 18 years+ - NCT06789172RecruitingPhase 1
New drug OKN4395 with or without pembrolizumab for solid tumors
This trial tests a new oral drug called OKN4395, which targets a COX2-related immune pathway, alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors. It may be an option if you have certain types of cancer that have stopped responding to other treatments.
Beverly Hills, CaliforniaAges 18 years+ - NCT07223047RecruitingPhase 1/Phase 2
Study of BMS-986523 for advanced solid tumors with KRAS changes
This trial tests an experimental drug (BMS-986523) alone or with other cancer treatments for people with advanced solid tumors that have a specific change in the KRAS gene. It aims to see if the drug is safe and effective.
Baltimore, MarylandAges 18 years+ - NCT04824053Recruiting
Dairy products study for people at high risk of colon cancer
This trial studies whether specific dairy products (UNICLA-A2) can help lower the risk of future colon problems in people considered high risk for colorectal cancer. You may be asked to keep using dairy consistently and undergo colon checks as part of usual follow-up.
Zaragoza, ZaragozaAges 18–80 - NCT06853496RecruitingPhase 1
RK-582 for advanced colorectal cancer
This trial tests a new type of pill called RK-582 that may help block the growth of colorectal cancer cells. It is for people whose cancer has spread and hasn't gotten better with other treatments.
Koto-ku, TokyoAges 18 years+
Hear when a new Colorectal Cancer Screening trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for colorectal cancer screening?
- Yes. Clin2 currently lists 370 recruiting colorectal cancer screening studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a colorectal cancer screening trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a colorectal cancer screening trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.